• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply

Welcome to the international HTA database

CSV RIS
Showing [23447 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2013     Andalusian Health Technology Assessment Area (AETSA) [Safety of natural therapies with direct impact on health: Acupuncture]
2013     Andalusian Health Technology Assessment Area (AETSA) [Safety and efficacy of therapeutic hypothermia for acute ischemic stroke. Systematic review and Meta-analysis]
2012     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Safety and efficacy of the different techniques of left ventricular reconstructive surgery]
2020     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Safety and efficacy of Thai massage as a therapeutic intervention in clinical pathologies]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Safety and efficacy of reusable versus new electrophysiology catheters]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Safety and efficacy of reusable versus new balloon catheters for angioplasty]
2005     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Safety and efficacy of reusable versus new balloon catheters for angioplasty]
2011     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Safety and efficacy of metformin in improving clinical, hormonal and metabolic features of polycystic ovary syndrome. Systematic review and meta-analysis ]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and efficacy of mechanical thrombectomy using stents retrievers in the treatment of acute isquemic stroke]
2015     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and efficacy of drug eluting balloon angioplasty for coronary artery stenosis: in-stent restenosis and de novo lesions]
2016     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and efficacy of antibody-coated stent for the treatment of de novo coronary artery disease]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Safety and effectiveness of percutaneous tricuspid valve repair]
2012     Andalusian Health Technology Assessment Area (AETSA) [Safety and effectiveness of oncolytic viruses in advanced cancer. systematic review of the literature]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and effectiveness of non-invasive management of pectus excavatum with vacuum bell therapy]
2016     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and effectiveness of LDL-aphaeresis in cerebrotendinous xanthomatosis]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Safety and cost-effectiveness of a diagnostic decision rule for suspected deep venous thrombosis in thrombosis in general practice]
2025     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Safety and clinical effectiveness of cryoanalgesia in pediatric patients after surgical intervention for pectus excavatum]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacubitril/valsartan: addendum to commission A15-60]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacubitril/valsartan (heart failure, children and adolescents) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacubitril/valsartan (heart failure, children and adolescents) – Addendum to Commission A23-56]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacubitril/valsartan - Benefit assessment according to §35a Social Code Book V]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Sacral nerve stimulation/neuromodulation in bladder and/or bowel incontinence]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Sacral nerve stimulation for the treatment of voiding dysfunction]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Sacral nerve stimulation for fecal incontinence]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Sacral nerve stimulation (SNS) for fecal incontinence]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab govitecan (breast cancer) – Addendum to Project A23-86]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab govitecan (breast cancer) - Addendum to Commission A21-154]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2020     National Committee for Technology Incorporation (CONITEC) [Ruxolitinib for the treatment of patients with primary myelofibrosis, post-polycythaemia vera myelofibrosis or post-essential thrombocythaemia myelofibrosis, in people with intermediate-2 or high-risk disease]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib (Addendum to Commission A15-13)]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ruxolitinib - Assessment according to § 35a (para. 1., sentence 10) Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rurioctocog alfa pegol (haemophilia A) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rucaparib (ovarian, fallopian tube or peritoneal cancer; treatment) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rucaparib (ovarian, fallopian tube or peritoneal cancer; maintenance treatment) - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rucaparib (maintenance treatment in ovarian cancer after first-line therapy) – Benefit assessment according to §35a Social Code Book V]
2009     Committee for New Health Technology Assessment (CNHTA) [RRM1 RNA RT-PCR quantification]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rozanolixizumab (myasthenia gravis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Roxadustat (anaemia) - Benefit assessment according to §35a Social Code Book V]
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Roux-en-Y gastric bypass for treating obesity]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Routine use of CYP-test in antipsychotic drug treatment - a health technology assessment]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for valoctocogene roxaparvovec: Review of the study protocol (Version 3.0) and statistical analysis plan (Version 3.0) – Fourth addendum to Project A22-20]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for talquetamab (multiple myeloma) - First addendum to Project A23-100]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for risdiplam acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version1.0) – Second addendum to Commission A21-131]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for etranacogene dezaparvovec (haemophilia B): Review of the study protocol (Version 2.0) and statistical analysis plan (Version 2.0) – Third addendum to Commission A22-83]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for etranacogene dezaparvovec (haemophilia B) acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 1.0) and the statistical analysis plan (Version 1.0) – Second addend]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for brexucabtagene autoleucel: Review of the study protocol (Version 2.0) and statistical analysis plan (Version 2.0) – Third Addendum to Commission A21-130]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Routine practice data collection for brexucabtagene autoleucel acc. to the Law for More Safety in the Supply of Medicines (GSAV): Evaluation of the study protocol (Version 3.0) and the statistical analysis plan (Version 3.0) – Fourth addendum to Commission]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Routine analysis requesting profiles in primary healthcare: comparison of guidelines and cost analyses in the Basque country]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Rotigotine for Parkinson’s disease]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Rotavirus vaccination - a health technology assessment]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ropeginterferon alfa-2b (polycythaemia vera) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Romosozumab (osteoporosis) - Addendum to Commission A20-24]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Romiplostim (Nplate) and eltrombopag (Revolade) for the treatment of immune thrombocytopenic purpura]
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Role of PET/CT with choline analogue radiotracers in the diagnosis and staging of prostate cancer]
2015     Finnish Office for Health Care Technology Assessment (Finohta) [Role of fractional exhaled nitric oxide (FeNO) measurement in the management of asthma with corticosteroids]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rolapitant (prevention of nausea and vomiting in chemotherapy) - Benefit assessment according to §35a Social Code Book V]
2017     Agenzia nazionale per i servizi sanitari regionali (Agenas) [Robotic surgery]
2010     Andalusian Health Technology Assessment Area (AETSA) [Robotic surgery using the da Vinci robotic telemanipulation system in hysterectomy]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter II: urological, gynecological, general and digestive surgery]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Robotic surgery in benign and malignant surgical pathology (urology, general and digestive surgery, cardiothoracic surgery, gynecology, endocrinology, ophthalmology, and head and neck surgery). Chapter I: cardiothoracic, endocrine, ophthalmological surgery, and head and neck surgery]
2011     The Regional Health Technology Assessment Centre (HTA-centrum) [Robotic surgery for benign gynecologic disease]
2010     Andalusian Health Technology Assessment Area (AETSA) [Robotic surgery by means of the da Vinci robotic telemanipulation system in general and digestive surgery]
2010     Andalusian Health Technology Assessment Area (AETSA) [Robotic surgery by means of the da Vinci robotic telemanipulation system in cardiovascular surgery]
2024     Norwegian Institute of Public Health (NIPH) [Robotic hysterectomy]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Robotic gynecological surgery]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Robotic Bronchoscopy for Lung Nodule Diagnostics. Horizon Scanning Technologies]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Robotic assisted laparoscopic surgery for cervical and endometrial cancer]
2015     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Robot-assisted surgery: a systematic review of effectiveness and safety for elected indications and accumulating costs]
2010     Andalusian Health Technology Assessment Area (AETSA) [Robot-assisted surgery using da Vinci robot telemanipulation in prostatectomy]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Robot-assisted rehabilitation for incomplete spinal cord injury]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted rectal resection for rectal cancer]
2024     Norwegian Institute of Public Health (NIPH) [Robot-assisted prostatectomy for prostate cancer]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Robot Assisted Radical Prostatectomy (RARP)]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Robot assisted orthopaedic surgery]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [Rivastigmine for delirium in intensive care patients, a double-blind, randomised placebo-controlled add-on trial]
2006     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Rituximab in patients with rheumatoid arthritis:systematic review and economic evaluation]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab for the treatment of patients with chronic lymphocytic leukemia]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab for the treatment of chronic immune thrombocytopenic purpura]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab for patients with diagnosed chronic neuromyelitis, myasthenia gravis and chronic inflammatory demyelinating polyneuropathy]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Rituximab biosimilars]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Risk-reducing surgery in BRCA1 or 2 mutation carriers]
2022     Austrian Institute for Health Technology Assessment (AIHTA) [Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess individual breast cancer risk, their utility and applicability in a breast cancer screening programme]
2007     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Risk-adjustment in health services evaluation]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [Risk factors at the regional level for suicide in the Korean elderly]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Risk factor analysis and probability of fragility fracture in a cohort of women with bone densitometry indication]
2019     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Risk and needs assessment regarding reoffending in adolescents]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Risdiplam in spinal muscular atrophy]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risdiplam (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risdiplam (spinal muscular atrophy) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risdiplam (spinal muscular atrophy, < 2 months) – Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (plaque psoriasis) - Second Addendum to Commission A19-41]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (plaque psoriasis) - Addendum to Commission A19-41]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn’s disease) - Benefit assessment according to § 35a SGB V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Risankizumab (Crohn disease) – Addendum to Commission A22-133]